139:, and colleagues showed that in most clinical cases, combination therapies are needed to avoid the evolution of resistance to targeted drugs. Furthermore, they find that the simultaneous administration of multiple targeted drugs minimizes the chance of relapse when no single mutation confers cross-resistance to both drugs.
77:
is a related term, referring to the use of multiple medications (without regard to whether they are for the same or separate conditions/diseases). Sometimes "polymedicine" is used to refer to pharmaceutical combination therapy. Most of these kinds of terms lack a universally consistent definition, so
121:
Combination therapy may seem costlier than monotherapy in the short term, but when it is used appropriately, it causes significant savings: lower treatment failure rate, lower case-fatality ratios, fewer side-effects than monotherapy, slower development of resistance, and thus less money needed for
146:
approaches have focused on targeting multiple biomarkers found in individual tumors by using combinations of drugs. However, with 300 FDA-approved cancer drugs on the market, there almost 45,000 possible two-drug combinations and almost 4.5 million three-drug combinations for to choose from. That
130:
Combination therapy has gained momentum in oncology in recent years, with various studies demonstrating higher response rates with combinations of drugs compared to monotherapies, and the FDA recently approving therapeutic combination regimens that demonstrated superior safety and efficacy to
717:
Monotherapy: The treatment of epilepsy with a single medication rather than a combination. Monotherapy has advantages over combining medications in many patients, including absence of drug-drug interactions, fewer side effects, simpler dosing, and lower cost. However, not all patients can be
375:
532:
Li, Xubin; Dowling, Elisabeth K.; Yan, Gonghong; Dereli, Zeynep; Bozorgui, Behnaz; Imanirad, Parisa; Elnaggar, Jacob H.; Luna, Augustin; Menter, David G.; Pilié, Patrick G.; Yap, Timothy A. (2022-05-02).
267:
Janku, Filip; Hong, David S.; Fu, Siqing; Piha-Paul, Sarina A.; Naing, Aung; Falchook, Gerald S.; Tsimberidou, Apostolia M.; Stepanek, Vanda M.; Moulder, Stacy L. (2014-01-30).
383:
376:"Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer | Novartis US"
324:
Musgrove, Elizabeth A.; Caldon, C. Elizabeth; Barraclough, Jane; Stone, Andrew; Sutherland, Robert L. (2011-07-07). "Cyclin D as a therapeutic target in cancer".
174:. Normally, monotherapy is selected because a single medication is adequate to treat the medical condition. However, monotherapies may also be used because of
404:
Korkut, A; Wang, W; Demir, E; Aksoy, BA; Jing, X; Molinelli, EJ; Babur, Ö; Bemis, DL; Onur Sumer, S; Solit, DB; Pratilas, CA; Sander, C (18 August 2015).
615:
170:
Monotherapy, or the use of a single therapy, can be applied to any therapeutic approach, but it is most commonly used to describe the use of a single
59:, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and
63:
to treat depression). 'Pharmaceutical' combination therapy may be achieved by prescribing/administering separate drugs, or, where available,
142:
Various systems biology methods must be used to discover combination therapies to overcome drug resistance in select cancer types. Recent
162:
Combination therapy with two or more antibiotics are often used in an effort to treat multi-drug resistant Gram-negative bacteria.
118:-based monotherapies for malaria are explicitly discouraged to avoid the problem of developing resistance to the newer treatment.
760:
701:
755:
591:
151:
406:"Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells"
507:
623:
736:
covers information on more than 1300 drug combinations in either clinical use or different testing stages.
457:"Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks"
765:
147:
level of complexity is one of the primary impediments to the growth of combination therapy in oncology.
49:
357:
143:
30:"Polytherapy" redirects here. For polytherapy in the sense of 4 or more medications at once, see
114:
since a pathogen or tumor is less likely to have resistance to multiple drugs simultaneously.
683:
665:
572:
554:
486:
437:
349:
341:
306:
288:
249:
68:
455:
Lee, MJ; Ye, AS; Gardino, AK; Heijink, AM; Sorger, PK; MacBeath, G; Yaffe, MB (11 May 2012).
673:
657:
562:
546:
476:
468:
427:
417:
333:
296:
280:
239:
229:
197:
179:
175:
136:
111:
742:
method for the discovery of anti-resistance drug combinations with network pharmacology.
678:
645:
567:
534:
481:
456:
432:
405:
301:
268:
244:
221:
749:
154:
has recently highlighted combination therapy as a top research priority in oncology.
361:
17:
132:
87:
74:
60:
31:
550:
284:
115:
110:. One major benefit of combination therapies is that they reduce development of
64:
27:
Use of more than one medication or modality together to treat a single condition
472:
269:"Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors"
52:
or modality. Typically, the term refers to using multiple therapies to treat a
171:
669:
646:"Combination Therapy for Treatment of Infections with Gram-Negative Bacteria"
558:
345:
292:
222:"Evolutionary dynamics of cancer in response to targeted combination therapy"
705:
535:"Precision Combination Therapies Based on Recurrent Oncogenic Coalterations"
733:
687:
576:
490:
441:
353:
310:
253:
194:, a medication which contains a combination of multiple active ingredients
661:
191:
422:
234:
99:
91:
56:
45:
95:
739:
337:
107:
644:
Tamma, P. D.; Cosgrove, S. E.; Maragakis, L. L. (2012-07-01).
103:
592:"By the Numbers: Combination Therapy in Oncology | CureMatch"
131:
monotherapies. In a recent study about solid cancers,
508:"Drug Combinations to Overcome Treatment Resistance"
86:
Conditions treated with combination therapy include
220:Bozic; Reiter; Allen; et al. (June 25, 2013).
616:"Combination Therapies for Cancer - Annual Plan"
78:caution and clarification are often advisable.
8:
215:
213:
677:
566:
480:
431:
421:
300:
243:
233:
209:
7:
502:
500:
71:(such as fixed-dose combinations).
25:
122:the development of new drugs.
1:
650:Clinical Microbiology Reviews
718:controlled with monotherapy.
551:10.1158/2159-8290.CD-21-0832
285:10.1016/j.celrep.2013.12.035
67:that contain more than one
782:
734:Drug combination database.
473:10.1016/j.cell.2012.03.031
380:www.pharma.us.novartis.com
29:
620:National Cancer Institute
512:National Cancer Institute
152:National Cancer Institute
590:Culjat, M (2017-05-11).
48:that uses more than one
166:Contrast to monotherapy
326:Nature Reviews. Cancer
176:unwanted side effects
740:Perturbation biology
662:10.1128/CMR.05041-11
228:. 2:e00747: e00747.
158:Bacterial infections
18:Adjunctive treatment
761:Medical terminology
423:10.7554/elife.04640
235:10.7554/eLife.00747
38:Combination therapy
756:Medical treatments
144:precision medicine
180:drug interactions
69:active ingredient
16:(Redirected from
773:
721:
720:
714:
713:
704:. Archived from
698:
692:
691:
681:
641:
635:
634:
632:
631:
622:. Archived from
612:
606:
605:
603:
602:
587:
581:
580:
570:
539:Cancer Discovery
529:
523:
522:
520:
519:
504:
495:
494:
484:
452:
446:
445:
435:
425:
401:
395:
394:
392:
391:
382:. Archived from
372:
366:
365:
321:
315:
314:
304:
264:
258:
257:
247:
237:
217:
198:Combination drug
21:
781:
780:
776:
775:
774:
772:
771:
770:
746:
745:
730:
725:
724:
711:
709:
700:
699:
695:
643:
642:
638:
629:
627:
614:
613:
609:
600:
598:
589:
588:
584:
545:(6): OF1–OF18.
531:
530:
526:
517:
515:
506:
505:
498:
454:
453:
449:
403:
402:
398:
389:
387:
374:
373:
369:
338:10.1038/nrc3090
323:
322:
318:
266:
265:
261:
219:
218:
211:
206:
188:
168:
160:
137:Bert Vogelstein
128:
112:drug resistance
84:
35:
28:
23:
22:
15:
12:
11:
5:
779:
777:
769:
768:
763:
758:
748:
747:
744:
743:
737:
729:
728:External links
726:
723:
722:
693:
656:(3): 450–470.
636:
607:
596:CureMatch Blog
582:
524:
496:
447:
396:
367:
332:(8): 558–572.
316:
279:(2): 377–387.
259:
208:
207:
205:
202:
201:
200:
195:
187:
184:
167:
164:
159:
156:
127:
124:
83:
80:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
778:
767:
764:
762:
759:
757:
754:
753:
751:
741:
738:
735:
732:
731:
727:
719:
708:on 2008-09-07
707:
703:
697:
694:
689:
685:
680:
675:
671:
667:
663:
659:
655:
651:
647:
640:
637:
626:on 2017-10-05
625:
621:
617:
611:
608:
597:
593:
586:
583:
578:
574:
569:
564:
560:
556:
552:
548:
544:
540:
536:
528:
525:
513:
509:
503:
501:
497:
492:
488:
483:
478:
474:
470:
467:(4): 780–94.
466:
462:
458:
451:
448:
443:
439:
434:
429:
424:
419:
415:
411:
407:
400:
397:
386:on 2017-10-04
385:
381:
377:
371:
368:
363:
359:
355:
351:
347:
343:
339:
335:
331:
327:
320:
317:
312:
308:
303:
298:
294:
290:
286:
282:
278:
274:
270:
263:
260:
255:
251:
246:
241:
236:
231:
227:
223:
216:
214:
210:
203:
199:
196:
193:
190:
189:
185:
183:
181:
178:or dangerous
177:
173:
165:
163:
157:
155:
153:
148:
145:
140:
138:
134:
125:
123:
119:
117:
113:
109:
105:
101:
97:
93:
89:
81:
79:
76:
72:
70:
66:
62:
58:
55:
51:
47:
43:
39:
33:
19:
766:Pharmacology
716:
710:. Retrieved
706:the original
696:
653:
649:
639:
628:. Retrieved
624:the original
619:
610:
599:. Retrieved
595:
585:
542:
538:
527:
516:. Retrieved
514:. 2016-12-21
511:
464:
460:
450:
413:
409:
399:
388:. Retrieved
384:the original
379:
370:
329:
325:
319:
276:
273:Cell Reports
272:
262:
225:
169:
161:
149:
141:
133:Martin Nowak
129:
120:
88:tuberculosis
85:
75:Polypharmacy
73:
65:dosage forms
61:talk therapy
53:
41:
37:
36:
32:Polypharmacy
126:In oncology
116:Artemisinin
42:polytherapy
750:Categories
712:2008-04-02
702:"Glossary"
630:2017-10-03
601:2017-10-03
518:2017-10-03
390:2017-10-03
204:References
172:medication
50:medication
670:0893-8512
559:2159-8274
346:1474-1768
293:2211-1247
688:22763634
577:35412613
491:22579283
442:26284497
362:29093377
354:21734724
311:24440717
254:23805382
192:Polypill
186:See also
679:3416487
568:9524464
482:3501264
433:4539601
302:4409143
245:3691570
100:malaria
92:leprosy
57:disease
46:therapy
686:
676:
668:
575:
565:
557:
489:
479:
440:
430:
360:
352:
344:
309:
299:
291:
252:
242:
102:, and
96:cancer
54:single
410:eLife
358:S2CID
226:eLife
684:PMID
666:ISSN
573:PMID
555:ISSN
487:PMID
461:Cell
438:PMID
350:PMID
342:ISSN
307:PMID
289:ISSN
250:PMID
150:The
108:AIDS
82:Uses
674:PMC
658:doi
563:PMC
547:doi
477:PMC
469:doi
465:149
428:PMC
418:doi
334:doi
297:PMC
281:doi
240:PMC
230:doi
104:HIV
44:is
40:or
752::
715:.
682:.
672:.
664:.
654:25
652:.
648:.
618:.
594:.
571:.
561:.
553:.
543:12
541:.
537:.
510:.
499:^
485:.
475:.
463:.
459:.
436:.
426:.
416:.
412:.
408:.
378:.
356:.
348:.
340:.
330:11
328:.
305:.
295:.
287:.
275:.
271:.
248:.
238:.
224:.
212:^
182:.
135:,
98:,
94:,
90:,
690:.
660::
633:.
604:.
579:.
549::
521:.
493:.
471::
444:.
420::
414:4
393:.
364:.
336::
313:.
283::
277:6
256:.
232::
106:/
34:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.